SARS-CoV-2 is known to enter human cells with the help of angiotensin-converting enzyme 2, which can be up-regulated by inhibitors of the renin–angiotensin system (RAS). A study tested the discontinuation v/s continuation of chronic treatment with ACE-inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in the course of recent-onset COVID-19.

The researchers found no significant effect on the maximum severity of COVID-19 on discontinuation of RAS-inhibition, rather found a faster and better recovery. So, they suggested the temporary discontinuation of RAS inhibition at the onset of COVID-19 to be safe, unharmful and beneficial for the patient.

The study highlighted the decision to continue or discontinue the drug to be made on an individual basis, scrutinizing the risk profile, the indication for RAS inhibition, availability of alternative therapies and outpatient monitoring options.